Background: Hepatocellular carcinoma (HCC) is the most prevalent kind of primary liver cancer and a significant cause of cancer-related mortality across the world.Sorafenib is considered as the approved drug of choice in advanced HCC, which is an oral multikinase inhibitor with effective antiproliferative and antiangiogenic effects.In India, there is currently insufficient data on the safety and efficacy of sorafenib in the treatment of HCC. Objective: The study aims to evaluate the safety and effectiveness of sorafenib therapy in advanced HCC. Methods: A prospective study of 66 patients administered with sorafenib for advanced HCC between June 2016- May 2017 was carried out in a single center with a mean follow-up of 3 months. The adverse events (AEs) were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Effectiveness was analyzed based on Alpha- Fetoprotein (AFP) levels from laboratory findings. The median age was 63 years (range 61-70) with the male to female ratio of 16:1. Results: The most commonly observed adverse events were fatigue (31.81%), hand foot syndrome (24.24%), and diarrhea(24.24%). A statistically significant decline in AFP levels was observed with sorafenib treatment (p=<0.001). Conclusion: Sorafenib appears to be beneficial for individuals with advanced HCC, regardless of the baseline condition.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.